Early-life lead exposure recapitulates the selective loss of parvalbumin-positive GABAergic interneurons and subcortical dopamine system hyperactivity present in schizophrenia

Translational Psychiatry

Volumn 5, Issue 3, 2015, Pages

  Stansfield, K H ^a   Ruby, K N ^a   Soares, B D ^a   McGlothan, J L ^a   Liu, X ^a   Guilarte, T R ^a  

^a Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; DOPAMINE; LEAD; PARVALBUMIN;

ANIMAL; BLOOD; BRAIN; CHEMICALLY INDUCED; COMPLICATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPERKINESIA; INTERNEURON; LEAD POISONING; LONG EVANS RAT; MALE; METABOLISM; PREGNANCY; PRENATAL EXPOSURE; RAT; RISK FACTOR; SCHIZOPHRENIA; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; BRAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOPAMINE; FEMALE; GAMMA-AMINOBUTYRIC ACID; HYPERKINESIS; INTERNEURONS; LEAD; LEAD POISONING; MALE; PARVALBUMINS; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RATS; RATS, LONG-EVANS; RISK FACTORS; SCHIZOPHRENIA;

EID: 85014784392     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/TP.2014.147     Document Type: Article

References (97)

1. Weinberger DR. On the plausibility of "the neurodevelopmental hypothesis" of schizophrenia. Neuropsychopharmacology 1996; 14: 1S–11S.
2. Insel TR. Rethinking schizophrenia. Nature 2010; 468: 187–193.
3. Tsuang MT, Stone WS, Faraone SV. Genes, environment and schizophrenia. Br J Psychiatry Suppl 2001; 40: s18–s24.
4. van Os J, Kenis G, Rutten BP. The environment and schizophrenia. Nature 2010; 468: 203–212.
5. Brown AS. The environment and susceptibility to schizophrenia. Prog Neurobiol 2011; 93: 23–58.
6. Brown AS, Susser ES. Prenatal nutritional deficiency and risk of adult schizo-phrenia. Schizophr Bull 2008; 34: 1054–1063.
7. Munk-Jorgensen P, Ewald H. Epidemiology in neurobiological research: exem-plified by the influenza-schizophrenia theory. Br J Psychiatry Suppl 2001; 40: s30–s32.
8. Baghurst PA, McMichael AJ, Wigg NR, Vimpani GV, Robertson EF, Roberts RJ et al. Environmental exposure to lead and children's intelligence at the age of seven years. The Port Pirie Cohort Study. N Engl J Med 1992; 327: 1279–1284.
9. Bellinger D, Sloman J, Leviton A, Rabinowitz M, Needleman HL, Waternaux C. Low-level lead exposure and children's cognitive function in the preschool years. Pediatrics 1991; 87: 219–227.
10. Canfield RL, Henderson CR Jr, Cory-Slechta DA, Cox C, Jusko TA, Lanphear BP. Intellectual impairment in children with blood lead concentrations below 10 microg per deciliter. N Engl J Med 2003; 348: 1517–1526.
11. Kordas K, Canfield RL, Lopez P, Rosado JL, Vargas GG, Cebrian ME et al. Deficits in cognitive function and achievement in Mexican first-graders with low blood lead concentrations. Environ Res 2006; 100: 371–386.
12. Lanphear BP, Hornung R, Khoury J, Yolton K, Baghurst P, Bellinger DC et al. Low-level environmental lead exposure and children's intellectual function: an inter-national pooled analysis. Environ Health Perspect 2005; 113: 894–899.
13. Liu J, Li L, Wang Y, Yan C, Liu X. Impact of low blood lead concentrations on IQ and school performance in Chinese children. PLoS One 2013; 8: e65230.
14. Needleman HL, Gunnoe C, Leviton A, Reed R, Peresie H, Maher C et al. Deficits in psychologic and classroom performance of children with elevated dentine lead levels. N Engl J Med 1979; 300: 689–695.
15. Tellez-Rojo MM, Bellinger DC, Arroyo-Quiroz C, Lamadrid-Figueroa H, Mercado-Garcia A, Schnaas-Arrieta L et al. Longitudinal associations between blood lead concentrations lower than 10 microg/dL and neurobehavioral development in environmentally exposed children in Mexico City. Pediatrics 2006; 118: e323–e330.
16. Tong S, Baghurst P, McMichael A, Sawyer M, Mudge J. Lifetime exposure to environmental lead and children's intelligence at 11-13 years: the Port Pirie cohort study. BMJ 1996; 312: 1569–1575.
17. Wasserman GA, Liu X, Popovac D, Factor-Litvak P, Kline J, Waternaux C et al. The Yugoslavia Prospective Lead Study: contributions of prenatal and postnatal lead exposure to early intelligence. Neurotoxicol Teratol 2000; 22: 811–818.
18. Wasserman GA, Staghezza-Jaramillo B, Shrout P, Popovac D, Graziano J. The effect of lead exposure on behavior problems in preschool children. Am J Public Health 1998; 88: 481–486.
19. Bouchard MF, Bellinger DC, Weuve J, Matthews-Bellinger J, Gilman SE, Wright RO et al. Blood lead levels and major depressive disorder, panic disorder, and generalized anxiety disorder in US young adults. Arch Gen Psychiatry 2009; 66: 1313–1319.
20. McFarlane AC, Searle AK, Van Hooff M, Baghurst PA, Sawyer MG, Galletly C et al. Prospective associations between childhood low-level lead exposure and adult mental health problems: the Port Pirie cohort study. Neurotoxicology 2013; 39: 11–17.
21. Needleman HL, Riess JA, Tobin MJ, Biesecker GE, Greenhouse JB. Bone lead levels and delinquent behavior. JAMA 1996; 275: 363–369.
22. Peters JL, Kubzansky LD, Ikeda A, Spiro A 3rd, Wright RO, Weisskopf MG et al. Childhood and adult socioeconomic position, cumulative lead levels, and pessi-mism in later life: the VA Normative Aging Study. Am J Epidemiol 2011; 174: 1345–1353.
23. Wright JP, Dietrich KN, Ris MD, Hornung RW, Wessel SD, Lanphear BP et al. Association of prenatal and childhood blood lead concentrations with criminal arrests in early adulthood. PLoS Med 2008; 5: e101.
24. Opler MG, Brown AS, Graziano J, Desai M, Zheng W, Schaefer C et al. Prenatal lead exposure, delta-aminolevulinic acid, and schizophrenia. Environ Health Perspect 2004; 112: 548–552.
25. Opler MG, Buka SL, Groeger J, McKeague I, Wei C, Factor-Litvak P et al. Prenatal exposure to lead, delta-aminolevulinic acid, and schizophrenia: further evidence. Environ Health Perspect 2008; 116: 1586–1590.
26. Cecil KM, Brubaker CJ, Adler CM, Dietrich KN, Altaye M, Egelhoff JC et al. Decreased brain volume in adults with childhood lead exposure. PLoS Med 2008; 5: e112.
27. Schwartz BS, Stewart WF, Bolla KI, Simon PD, Bandeen-Roche K, Gordon PB et al. Past adult lead exposure is associated with longitudinal decline in cognitive function. Neurology 2000; 55: 1144–1150.
28. Stewart WF, Schwartz BS, Davatzikos C, Shen D, Liu D, Wu X et al. Past adult lead exposure is linked to neurodegeneration measured by brain MRI. Neurology 2006; 66: 1476–1484.
29. Stewart WF, Schwartz BS. Effects of lead on the adult brain: a 15-year exploration. Am J Ind Med 2007; 50: 729–739.
30. Brubaker CJ, Dietrich KN, Lanphear BP, Cecil KM. The influence of age of lead exposure on adult gray matter volume. Neurotoxicology 2010; 31: 259–266.
31. Brubaker CJ, Schmithorst VJ, Haynes EN, Dietrich KN, Egelhoff JC, Lindquist DM et al. Altered myelination and axonal integrity in adults with childhood lead exposure: a diffusion tensor imaging study. Neurotoxicology 2009; 30: 867–875.
32. Guilarte TR, Opler M, Pletnikov M. Is lead exposure in early life an environmental risk factor for Schizophrenia? Neurobiological connections and testable hypoth-eses. Neurotoxicology 2012; 33: 560–574.
33. Abazyan B, Dziedzic J, Hua K, Abazyan S, Yang C, Mori S et al. Chronic exposure of mutant DISC1 mice to lead produces sex-dependent abnormalities consistent with schizophrenia and related mental disorders: a gene-environment interaction study. Schizophr Bull 2014; 40: 575–584.
34. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995; 52: 998–1007.
35. Coyle JT, Tsai G. NMDA receptor function, neuroplasticity, and the pathophysiology of schizophrenia. Int Rev Neurobiol 2004; 59: 491–515.
36. Snyder MA, Gao WJ. NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia. Front Cell Neurosci 2013; 7: 31.
37. Alkondon M, Costa AC, Radhakrishnan V, Aronstam RS, Albuquerque EX. Selective blockade of NMDA-activated channel currents may be implicated in learning deficits caused by lead. FEBS Lett 1990; 261: 124–130.
38. Guilarte TR, Miceli RC. Age-dependent effects of lead on [3H]MK-801 binding to the NMDA receptor-gated ionophore: in vitro and in vivo studies. Neurosci Lett 1992; 148: 27–30.
39. Gavazzo P, Zanardi I, Baranowska-Bosiacka I, Marchetti C. Molecular determinants of Pb2+ interaction with NMDA receptor channels. Neurochem Int 2008; 52: 329–337.
40. Toscano CD, Hashemzadeh-Gargari H, McGlothan JL, Guilarte TR. Developmental Pb2+ exposure alters NMDAR subtypes and reduces CREB phosphorylation in the rat brain. Brain Res Dev Brain Res 2002; 139: 217–226.
41. Toscano CD, Guilarte TR. Lead neurotoxicity: from exposure to molecular effects. Brain Res Brain Res Rev 2005; 49: 529–554.
42. Sheng M, Cummings J, Roldan LA, Jan YN, Jan LY. Changing subunit composition of heteromeric NMDA receptors during development of rat cortex. Nature 1994; 368: 144–147.
43. Quinlan EM, Philpot BD, Huganir RL, Bear MF. Rapid, experience-dependent expression of synaptic NMDA receptors in visual cortex in vivo. Nat Neurosci 1999; 2: 352–357.
44. Bellone C, Nicoll RA. Rapid bidirectional switching of synaptic NMDA receptors. Neuron 2007; 55: 779–785.
45. Matta JA, Ashby MC, Sanz-Clemente A, Roche KW, Isaac JT. mGluR5 and NMDA receptors drive the experience-and activity-dependent NMDA receptor NR2B to NR2A subunit switch. Neuron 2011; 70: 339–351.
46. Nihei MK, Desmond NL, McGlothan JL, Kuhlmann AC, Guilarte TR. N-methyl-D-aspartate receptor subunit changes are associated with lead-induced deficits of long-term potentiation and spatial learning. Neuroscience 2000; 99: 233–242.
47. McGlothan JL, Karcz-Kubicha M, Guilarte TR. Developmental lead exposure impairs extinction of conditioned fear in young adult rats. Neurotoxicology 2008; 29: 1127–1130.
48. Hashimoto T, Volk DW, Eggan SM, Mirnics K, Pierri JN, Sun Z et al. Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J Neurosci 2003; 23: 6315–6326.
49. Hashimoto T, Bazmi HH, Mirnics K, Wu Q, Sampson AR, Lewis DA. Conserved regional patterns of GABA-related transcript expression in the neocortex of subjects with schizophrenia. Am J Psychiatry 2008; 165: 479–489.
50. Lewis DA, Gonzalez-Burgos G. Pathophysiologically based treatment interventions in schizophrenia. Nat Med 2006; 12: 1016–1022.
51. Mellios N, Huang HS, Baker SP, Galdzicka M, Ginns E, Akbarian S. Molecular determinants of dysregulated GABAergic gene expression in the prefrontal cortex of subjects with schizophrenia. Biol Psychiatry 2009; 65: 1006–1014.
52. Fung SJ, Webster MJ, Sivagnanasundaram S, Duncan C, Elashoff M, Weickert CS. Expression of interneuron markers in the dorsolateral prefrontal cortex of the developing human and in schizophrenia. Am J Psychiatry 2010; 167: 1479–1488.
53. Volk DW, Matsubara T, Li S, Sengupta EJ, Georgiev D, Minabe Y et al. Deficits in transcriptional regulators of cortical parvalbumin neurons in schizophrenia. Am J Psychiatry 2012; 169: 1082–1091.
54. Uhlhaas PJ, Singer W. Abnormal neural oscillations and synchrony in schizo-phrenia. Nat Rev Neurosci 2010; 11: 100–113.
55. Volman V, Behrens MM, Sejnowski TJ. Downregulation of parvalbumin at cortical GABA synapses reduces network gamma oscillatory activity. J Neurosci 2011; 31: 18137–18148.
56. Gandal MJ, Sisti J, Klook K, Ortinski PI, Leitman V, Liang Y et al. GABAB-mediated rescue of altered excitatory-inhibitory balance, gamma synchrony and behavioral deficits following constitutive NMDAR-hypofunction. Transl Psychiatry 2012; 2: e142.
57. Kocsis B. Differential role of NR2A and NR2B subunits in N-methyl-D-aspartate receptor antagonist-induced aberrant cortical gamma oscillations. Biol Psychiatry 2012; 71: 987–995.
58. Belforte JE, Zsiros V, Sklar ER, Jiang Z, Yu G, Li Y et al. Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nat Neurosci 2010; 13: 76–83.
59. Cochran SM, Fujimura M, Morris BJ, Pratt JA. Acute and delayed effects of phencyclidine upon mRNA levels of markers of glutamatergic and GABAergic neurotransmitter function in the rat brain. Synapse 2002; 46: 206–214.
60. Keilhoff G, Becker A, Grecksch G, Wolf G, Bernstein HG. Repeated application of ketamine to rats induces changes in the hippocampal expression of parvalbumin, neuronal nitric oxide synthase and cFOS similar to those found in human schi-zophrenia. Neuroscience 2004; 126: 591–598.
61. Abekawa T, Ito K, Nakagawa S, Koyama T. Prenatal exposure to an NMDA receptor antagonist, MK-801 reduces density of parvalbumin-immunoreactive GABAergic neurons in the medial prefrontal cortex and enhances phencyclidine-induced hyperlocomotion but not behavioral sensitization to methamphetamine in postpubertal rats. Psychopharmacology (Berl) 2007; 192: 303–316.
62. Kittelberger K, Hur EE, Sazegar S, Keshavan V, Kocsis B. Comparison of the effects of acute and chronic administration of ketamine on hippocampal oscillations: relevance for the NMDA receptor hypofunction model of schizophrenia. Brain Struct Funct 2012; 217: 395–409.
63. Kaalund SS, Riise J, Broberg BV, Fabricius K, Karlsen AS, Secher T et al. Differential expression of parvalbumin in neonatal phencyclidine-treated rats and socially isolated rats. J Neurochem 2013; 124: 548–557.
64. Carlsson A. The neurochemical circuitry of schizophrenia. Pharmacopsychiatry 2006; 39 Suppl 1: S10–S14.
65. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 1996; 93: 9235–9240.
66. Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 1997; 94: 2569–2574.
67. Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M et al. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 1998; 155: 761–767.
68. Abi-Dargham A, van de Giessen E, Slifstein M, Kegeles LS, Laruelle M. Baseline and amphetamine-stimulated dopamine activity are related in drug-naive schizophrenic subjects. Biol Psychiatry 2009; 65: 1091–1093.
69. Lodge DJ, Grace AA. Hippocampal dysregulation of dopamine system function and the pathophysiology of schizophrenia. Trends Pharmacol Sci 2011; 32: 507–513.
70. Del Arco A, Segovia G, Mora F. Blockade of NMDA receptors in the prefrontal cortex increases dopamine and acetylcholine release in the nucleus accumbens and motor activity. Psychopharmacology (Berl) 2008; 201: 325–338.
71. Dorph-Petersen KA, Lewis DA. Stereological approaches to identifying neuro-pathology in psychosis. Biol Psychiatry 2011; 69: 113–126.
72. Sheleg M, Yochum CL, Wagner GC, Zhou R, Richardson JR. Ephrin-A5 deficiency alters sensorimotor and monoaminergic development. Behav Brain Res 2013; 236: 139–147.
73. Grace AA. Dopamine system dysregulation by the ventral subiculum as the common pathophysiological basis for schizophrenia psychosis, psychostimulant abuse, and stress. Neurotox Res 2010; 18: 367–376.
74. Gether U, Andersen PH, Larsson OM, Schousboe A. Neurotransmitter transporters: molecular function of important drug targets. Trends Pharmacol Sci 2006; 27: 375–383.
75. Akbarian S, Kim JJ, Potkin SG, Hagman JO, Tafazzoli A, Bunney WE Jr. et al. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch Gen Psychiatry 1995; 52: 258–266.
76. Bitanihirwe BK, Lim MP, Kelley JF, Kaneko T, Woo TU. Glutamatergic deficits and parvalbumin-containing inhibitory neurons in the prefrontal cortex in schizo-phrenia. BMC Psychiatry 2009; 9: 71.
77. Beasley CL, Zhang ZJ, Patten I, Reynolds GP. Selective deficits in prefrontal cortical GABAergic neurons in schizophrenia defined by the presence of calcium-binding proteins. Biol Psychiatry 2002; 52: 708–715.
78. Volk DW, Austin MC, Pierri JN, Sampson AR, Lewis DA. Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia. Arch Gen Psychiatry 2000; 57: 237–245.
79. Zhang ZJ, Reynolds GP. A selective decrease in the relative density of parvalbumin-immunoreactive neurons in the hippocampus in schizophrenia. Schizophr Res 2002; 55: 1–10.
80. Beasley CL, Reynolds GP. Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics. Schizophr Res 1997; 24: 349–355.
81. Braun I, Genius J, Grunze H, Bender A, Moller HJ, Rujescu D. Alterations of hip-pocampal and prefrontal GABAergic interneurons in an animal model of psychosis induced by NMDA receptor antagonism. Schizophr Res 2007; 97: 254–263.
82. Sadikot AF, Burhan AM, Belanger MC, Sasseville R. NMDA receptor antagonists influence early development of GABAergic interneurons in the mammalian striatum. Brain Res Dev Brain Res 1998; 105: 35–42.
83. Nihei MK, Guilarte TR. NMDAR-2A subunit protein expression is reduced in the hippocampus of rats exposed to Pb2+ during development. Brain Res Mol Brain Res 1999; 66: 42–49.
84. Kinney JW, Davis CN, Tabarean I, Conti B, Bartfai T, Behrens MM. A specific role for NR2A-containing NMDA receptors in the maintenance of parvalbumin and GAD67 immunoreactivity in cultured interneurons. J Neurosci 2006; 26: 1604–1615.
85. Xi D, Keeler B, Zhang W, Houle JD, Gao WJ. NMDA receptor subunit expression in GABAergic interneurons in the prefrontal cortex: application of laser micro-dissection technique. J Neurosci Methods 2009; 176: 172–181.
86. Buhl EH, Szilagyi T, Halasy K, Somogyi P. Physiological properties of anatomically identified basket and bistratified cells in the CA1 area of the rat hippocampus in vitro. Hippocampus 1996; 6: 294–305.
87. Grunze HC, Rainnie DG, Hasselmo ME, Barkai E, Hearn EF, McCarley RW et al. NMDA-dependent modulation of CA1 local circuit inhibition. J Neurosci 1996; 16: 2034–2043.
88. Xi D, Zhang W, Wang HX, Stradtman GG, Gao WJ. Dizocilpine (MK-801) induces distinct changes of N-methyl-D-aspartic acid receptor subunits in parvalbumin-containing interneurons in young adult rat prefrontal cortex. Int J Neuropsycho-pharmacol 2009; 12: 1395–1408.
89. Zhang Z, Sun QQ. Development of NMDA NR2 subunits and their roles in critical period maturation of neocortical GABAergic interneurons. Dev Neurobiol 2011; 71: 221–245.
90. Seeman P. Schizophrenia and dopamine receptors. Eur Neuropsychopharmacol 2013; 23: 999–1009.
91. Jaaro-Peled H, Niwa M, Foss CA, Murai R, de Los Reyes S, Kamiya A et al. Sub-cortical dopaminergic deficits in a DISC1 mutant model: a study in direct refer-ence to human molecular brain imaging. Hum Mol Genet 2013; 22: 1574–1580.
92. Zuch CL, O'Mara DJ, Cory-Slechta DA. Low-level lead exposure selectively enhances dopamine overflow in nucleus accumbens: an in vivo electrochemistry time course assessment. Toxicol Appl Pharmacol 1998; 150: 174–185.
93. Brunelin J, Fecteau S, Suaud-Chagny MF. Abnormal striatal dopamine transmission in schizophrenia. Curr Med Chem 2013; 20: 397–404.
94. Verina T, Rohde CA, Guilarte TR. Environmental lead exposure during early life alters granule cell neurogenesis and morphology in the hippocampus of young adult rats. Neuroscience 2007; 145: 1037–1047.
95. Commissaris RL, Tavakoli-Nezhad M, Barron AJ, Pitts DK. Effects of chronic low-level oral lead exposure on prepulse inhibition of acoustic startle in the rat. Neurotoxicol Teratol 2000; 22: 55–60.
96. Guilarte TR, Toscano CD, McGlothan JL, Weaver SA. Environmental enrichment reverses cognitive and molecular deficits induced by developmental lead expo-sure. Ann Neurol 2003; 53: 50–56.
97. Clune AL FH, Riederer AM. Mapping global environmental lead poisoning in children. J Health Pollut 2011; 1: 16–25.